In a sector often driven by clinical headlines, Enveric Biosciences has shifted attention back to the molecular level. The company today released new mechanistic data on its lead candidate, EB-003, offering one of the clearest looks yet at how next-generation neuroplastogens may separate therapeutic benefit from hallucinogenic risk.
